Newer anti-hyperglycemic agents in type 2 diabetes mellitus – Expanding the horizon

Apollo Medicine - Tập 10 - Trang 108-112 - 2013
Savita Jain1, Nitin Gupta1, Radhika Jindal1, Tuhin Dubey1, Niti Agarwal2, Asim Siddiqui2, S.K. Wangnoo3
1DNB Fellow, Department of Endocrinology, Indraprastha Apollo Hospital, Sarita Vihar, New Delhi, India
2Associate Consultant, Department of Endocrinology, Indraprastha Apollo Hospital, Sarita Vihar, New Delhi, India
3Senior Consultant, Department of Endocrinology, Indraprastha Apollo Hospital, Sarita Vihar, New Delhi, India

Tài liệu tham khảo

Uwaifo, 2005, Novel pharmacologic agents for type 2 diabetes, Endocrinol Metab Clin N Am, 34, 155, 10.1016/j.ecl.2004.11.006 Kalra, 2013, Recent advances in pathophysiology of diabetes: beyond the dirty dozen, J Pakistan Med Assoc, 63, 277 Nagasumi, 2009, Overexpression of GPR40 in pancreatic β-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice, Diabetes, 58, 1067, 10.2337/db08-1233 Kaku, 2013, Randomized double- blind, dose ranging study of TAK-875, a novel GPR40 agonist in Japanese patients with inadequately controlled type 2 diabetes, Diabetes Care, 36, 245, 10.2337/dc12-0872 Cheon, 2013, Latest research and development trends in non-insulin anti-diabetics, Arch Pharm Res, 36, 145, 10.1007/s12272-013-0016-7 Xiaoyun Zhu, Wenglong Huang and Hai Qian. GPR119 agonists: a novel strategy for type 2 diabetes treatment. Diabetes mellitus – insights and perspectives. Chapter 4. Edward C, Chao, Henry Robert R. SGLT2 inhibition – a novel strategy for diabetes treatment. Nat Rev Drug Discov AOP, published online 28 May 2010. Matschinsky, 2013, GKA's for diabetes therapy: why no clinically useful drug after two decades of trying?, Trends Pharmacol Sci, 34, 90, 10.1016/j.tips.2012.11.007 Ge, 2010, 11β hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development, Curr Med Chem, 17, 412, 10.2174/092986710790226147 Popoy, 2011, Novel protein tyrosine phosphatase 1B inhibitors: interaction requirements for improved intracellular efficacy in type 2 diabetes mellitus and obesity control, Biochem Biophys Res Commun, 410, 377, 10.1016/j.bbrc.2011.06.009 Denison, 2013, Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study, Diabetes Obes Metab, 15, 136, 10.1111/dom.12002 Baker, 2005, Glycogen phosphorylase inhibition in type 2 diabetes therapy, Diabetes, 54, 2453, 10.2337/diabetes.54.8.2453